250 related articles for article (PubMed ID: 9227442)
1. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
[TBL] [Abstract][Full Text] [Related]
2. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
Yoshimoto T; Naruse M; Shizume H; Naruse K; Tanabe A; Tanaka M; Tago K; Irie K; Muraki T; Demura H; Zardi L
Atherosclerosis; 1999 Aug; 145(2):333-40. PubMed ID: 10488961
[TBL] [Abstract][Full Text] [Related]
3. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
Fujita T; Sugiyama Y; Taketomi S; Sohda T; Kawamatsu Y; Iwatsuka H; Suzuoki Z
Diabetes; 1983 Sep; 32(9):804-10. PubMed ID: 6354788
[TBL] [Abstract][Full Text] [Related]
4. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
Murase K; Odaka H; Suzuki M; Tayuki N; Ikeda H
Diabetologia; 1998 Mar; 41(3):257-64. PubMed ID: 9541164
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
Yamashita H; Nagai Y; Takamura T; Nohara E; Kobayashi K
Metabolism; 2002 Apr; 51(4):403-8. PubMed ID: 11912544
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
10. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
Nakano R; Kurosaki E; Shimaya A; Kajikawa S; Shibasaki M
Eur J Pharmacol; 2006 Nov; 549(1-3):185-91. PubMed ID: 16989806
[TBL] [Abstract][Full Text] [Related]
11. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Tawfik MK
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):600-9. PubMed ID: 22774400
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Koike H
Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
Ohtomo S; Izuhara Y; Takizawa S; Yamada N; Kakuta T; van Ypersele de Strihou C; Miyata T
Kidney Int; 2007 Dec; 72(12):1512-9. PubMed ID: 17898696
[TBL] [Abstract][Full Text] [Related]
16. [Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Suzuki M; Odaka H
Nihon Rinsho; 2003 Jul; 61(7):1119-23. PubMed ID: 12877072
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
[TBL] [Abstract][Full Text] [Related]
18. Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
Tomiyoshi Y; Sakemi T; Aoki S; Miyazono M
Nephron; 2002 Dec; 92(4):860-7. PubMed ID: 12399633
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
Sugiyama Y; Shimura Y; Ikeda H
Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Feb; 28(2):340-52. PubMed ID: 19864959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
